Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease Mpro

Recently, Zhang and colleagues published a study in Science which reports about the crystal structure of the main protease (Mpro, 3CLpro) of SARS-CoV-21. The authors reported the X-ray structure of unliganded SARS-CoV-2 Mpro and its complex with α-ketoamide inhibitor after a modification from the previously designed inhibitor through incorporating P3-P2 amide bond into pyridone ring so as to increase its half-life in plasma. Finally the authors demonstrated that the crystal structure of Mpro provides a basis for designing of a potent inhibitor to the protease with a marked tropism to the lung and with ease of administration through inhalation.

An outbreak of series of acute respiratory illness caused by a novel coronavirus, SARS-CoV-2, caused a global threat in 20202. The world health organization (WHO) named the disease “COVID-19” and declared it as a world health emergency pandemic. Studying the crystal structure of targets for treatment is very crucial to know the mechanism of action of prospective drugs. A structural study on the coronavirus main protease 3CLpro inhibitor complex established designing of broad-spectrum halomethyl ketone inhibitors to the Coronaviridae family and demonstrated that these inhibitors form a thioether linkage with high affinity to the target3. Hilgenfeld’s group reported earlier that a structure-based design of peptidomimetic α-ketoamides are also effective broad-spectrum inhibitors to the main and 3C protease of coronaviruses and enteroviruses as demonstrated by crystal structure of inhibitor-protease complex4. The 3CL protease of coronaviruses facilitates viral assembly by cleaving polyproteins and most active compounds prevent disease progression by inhibiting viral proteases 5.

In their study, Zhang et al. modified the previously designed best inhibitor (11r) to increase its half-life in plasma, increase its solubility and reduce its binding to plasma proteins1. Here, the authors hide the P2-P3 amide bond into a pyridone ring to prevent it from cleavage by cellular proteases so that its plasma half-life is increased. To increase solubility of the inhibitor and reduce its binding to plasma proteins, the authors replaced the hydrophobic cinnamoyl moiety with a less hydrophobic Boc group.

The introduced pyridone ring should be compatible with the three-dimensional structure of the target which has a crucial role for effective inhibition. In order to confirm this, the authors solved the crystal structure of Mpro of SARS-CoV-2 at 1.75 Å resolution and found that the crystal structure is highly similar to that of SARS-CoV Mpro only with a 0.53 Å r.m.s difference between the two free enzymes. SARS-CoV-2 Mpro forms a tight dimer and has a contact interface mainly between domain II of molecule A and the NH2-terminal residues of molecule B where this dimerization is important for catalytic activity. Unlike SARS-CoV-2, SARS-CoV Mpro dimer has a polar interaction between the two domains III involving a 2.60 Å hydrogen bond between the side chain hydroxyl groups of Thr285 of each protomer which is also supported by a hydrophobic interaction between the side chain of Ile286 and Thr285. In SARS-CoV-2 Mpro, threonine is replaced with alanine and isoleucine with leucine. As suggested by authors, Alanine replacements change the enzyme dynamics and increase its catalytic activity by allowing the two domains III to be in a close contact; although, the catalytic activity of SARS-CoV-2 Mpro was only slightly higher with similar Kd of dimer dissociation (~2.5 μM).

The authors named the modified α-ketoamide inhibitor 13a. Compared to 11r, 13a has a 3 fold increase in plasma half-life in mice, highly soluble in plasma with a 19 fold increase in solubility in-vitro and a 13 fold increase in thermodynamic solubility. Further the binding of 13a with plasma proteins was reported to decrease to 97% as compared to 11r which showed 99% binding activity with plasma proteins. Provided these improvements, the structural modification resulted in loss of some inhibitory activities against the main protease of SARS-CoV-2 and 3C proteases of enteroviruses as evidenced by increased IC50 value.

The authors increase the antiviral activity of 13b against beta coronaviruses of clade b by sacrificing the broad-spectrum nature of 13a through replacing the P2 cyclohexyl moiety in 13a with a small cyclopropyl in 13b. The authors determined the X-ray structure of α-ketoamide 13b and SARS-CoV-2 Mpro complex at 1.95 and 2.20 Å resolution. In one of the structures, the authors found that the key residue, Glu166, forms inactive conformation in protomer B while the 13b compound is bound in the same fashion as in molecule A. Authors also found that the inhibitor binds to the shallow substrate-binding site at the surface of protomers between domains I and II in the inhibited SARS-CoV-2 Mpro.

The Boc group was removed in compound 14b resulting in inactive form which means the Boc group is necessary to cross the cellular membrane and even more hydrophobic moiety may be advantageous provided that it may result in increased plasma protein binding. Hilgenfeld’s group assessed the pharmacokinetics of 13a and 13b and found that the absorption-distribution-metabolism-excretion of both compounds was similar with a 90% binding to human plasma proteins. The 13b showed less clearance compared to 13a and good tropism to the lungs with a well-tolerated administration through inhalation in mice. Taken together, the authors designed α-ketoamide inhibitors with improved inhibition efficiency against recombinant SARS-CoV-2 Mpro to suppress disease progression (Fig. 1). Their work provides insights into the development of more potent pyridone containing anti-coronaviral drugs. Future structural-functional studies are recommended to improve the efficacy of targeted therapies to tackle the emerging pandemics due to coronaviruses.

Fig. 1

Inhibitors of protease Mpro prevent the replication of SARS-CoV-2. After entering into the host cell, SARS-CoV-2 releases its genomic RNA. The process of translation yields polyproteins pp1a and pp1ab, which are cleaved to the main protease Mpro and nonstructural proteins (nsps). Mpro is involved in the producing of nsps. Nsps is essential for assembling the viral replication transcription complex (RTC) to engage in RNA synthesis. Once inhibitors, such as 11r, 13a, and 13b, act in the cell, they bind to Mpro and inhibit the activity of this enzyme, resulting in failure of virion assembly. Ultimately, host cell fails to release the new intact virions. Colored box highlight the modifications from 11r to 14b. Due to lacking Boc group, 14b could not cross the cellular membrane to inhibit viral replication


  1. 1.

    Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 368, 409–412, (2020).

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Hui, D. S. et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J. Infect. Dis. 91, 264–266 (2020).

    CAS  Article  Google Scholar 

  3. 3.

    Bacha, U. et al. Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro). Chem. Biol. Drug Des. 72, 34–49 (2008).

    CAS  Article  Google Scholar 

  4. 4.

    Zhang, L. et al. Alpha-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. J. Med Chem. (2020).

  5. 5.

    Hsu, M. F. et al. Mechanism of the maturation process of SARS-CoV 3CL protease. J. Biol. Chem. 280, 31257–31266 (2005).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Tengchuan Jin.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mengist, H.M., Fan, X. & Jin, T. Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease Mpro. Sig Transduct Target Ther 5, 67 (2020).

Download citation

Further reading